Incongruent reduction of dopamine transporter availability in different subgroups of alcohol dependence

Che-Hung Yen (MD)a,b, Mei-Chen Shih (MS)c, Cheng-Yi Cheng (MD, PhD)d, Kuo-Hsing Ma (PhD)e, Ru-Band Lu (MD)f, San-Yuan Huang (MD, PhD)ac.*

Abstract
The dopamine transporter (DAT) plays a crucial role in the pathogenesis of alcohol dependence (AD) and major depression (MD), and males have more risk factors for the development of AD. However, imaging studies on brain DAT availability in males with AD comorbid with MD (AD/MD) are limited, and the association of DAT availability with cognitive function and depressive scores in patients with AD/MD has not been analyzed. Hence, this study examined the relationship between brain DAT availability, cognitive function, and depressive symptoms in different subgroups of males with AD.

Single-photon emission computed tomography imaging with 99mTc-TRODAT-1 as a ligand was used to measure striatal DAT availability in 49 patients with AD (28 pure AD and 21 AD/MD) and 24 age- and sex-matched healthy volunteers. The Wisconsin Card Sorting Test (WCST) and 17-item Hamilton Depression Rating Scale were used to assess neurocognitive function and depressive scores, respectively. Patients with AD showed a significant reduction of DAT availability in 3 brain regions (P < 0.001), and this reduction was more pronounced in the patients with pure AD compared to healthy controls. The patients with AD showed significantly poorer performance on the WCST, but only in the control group was DAT availability significantly negatively correlated with total errors and perseverative errors (P < 0.001).

These preliminary findings suggest that DAT availability is associated with neurocognitive function, and incongruent reduction of DAT may play a pathophysiological role in different subgroups of AD. In addition, decreased DAT availability may be associated with the severity of depressive symptoms in patients with AD/MD.

Abbreviations: [123]I-beta-CIT (2beta-carbomethoxy-3beta-(4-iodophenyl)tropane), 99mTc-TRODAT-1 = [2][3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3,2,1]-oct-2-yl]-methyl][2-mercaptopethyl][aminol][ethyl][amino][ethanethiolato[3-])N2,N2,S2,S2[exo-[1-R-exo-exo-]-[99mTc]-technetium, AD = alcohol dependence, AD/MD = alcohol dependence comorbid major depression, CSF = cerebrospinal fluid, CT = computed tomography, DAT = dopamine transporter, DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision, GEE = generalized estimating equation, HDRS = 17-item Hamilton Depression Rating Scale, HVA = homovanillic acid, MRI = magnetic resonance imaging, ROIs = regions of interest, SADS-L = Schedule of Affective Disorder and Schizophrenia-Lifetime, SPECT = single-photon emission computed tomography, SUR = specific uptake ratio, WCST = Wisconsin Card Sorting Test.

Keywords: alcohol dependence, cognitive function, dopamine transporter, major depression

1. Introduction

There is much evidence to suggest that dysfunction of the central dopaminergic system is a crucial factor in the development of alcoholism[1,2] and depressive disorder.[3] Low concentrations of homovanillic acid (a metabolite of dopamine) have been found in the cerebrospinal fluid of individuals with early-onset alcoholism[4] and depressive patients.[5] Hence, reduced dopaminergic transmission may contribute to specific behavioral symptoms of addiction and depression. The dopamine transporter (DAT) is a membrane-spanning protein[6] responsible for the reuptake of dopamine from the synaptic space into the presynaptic neuron.
Striatal dopamine levels, which reflect the intraneuronal vesicular storage pool of dopamine, were reduced in DAT knockout mice. Therefore, the DAT plays a crucial role in the regulation of synaptic dopamine levels.

Alcohol is a highly addictive substance, and continuing alcohol abuse disrupts the dopaminergic system in the brain. Previous brain imaging studies using single-photon emission computed tomography (SPECT) found a reduction in striatal DAT levels in patients with alcohol dependence (AD). In addition, studies using postmortem human whole-hemisphere autoradiography also suggest that DAT density is lower in alcoholics. Depression is a common comorbidity in patients with AD.

Reduced dopamine metabolism in the frontal areas, including the anterior cingulate gyrus and orbitofrontal cortex, has been found in patients with AD; these regions belong to areas of the cortex associated with executive function and attention. In previous studies, cognitive deficits in attention, cognition, visuospatial skills, and memory have been recorded in patients with AD. The Wisconsin Card Sorting Test (WCST) is a well-established test for measurement of impaired cognitive flexibility. However, investigation of differences in striatal DAT availability as it relates to the WCST within different subgroups of AD has been limited.

MD is a common comorbidity of AD and dopaminergic dysfunction plays a critical role in the development of AD and MD. Hence, it is important to elucidate the role of the DAT in AD and with and without MD. The prevalence rates for alcohol use disorders differ widely between males and females, and males are more likely to possess the exogenous risks and endogenous vulnerabilities associated with alcohol abuse. Therefore, this study aimed to investigate striatal DAT availability and its relationship to cognitive function specifically in male patients with pure AD and AD/MD, as compared to healthy male controls. We hypothesized that the 3 groups would show differences in both striatal DAT availability and the WCST scores. Reduced DAT availability would correlate with the WCST scores. In addition, we investigated a putative association between the depressive score and striatal DAT availability in the human brain.

2. Materials and methods

2.1. Participants

Individuals who voluntarily sought treatment for AD at the Tri-Service General Hospital, National Defense Medical Center, Taiwan, between 2010 and 2014 and who met inclusion/exclusion criteria were eligible to participate. All participants were older than 20 years of age and all patients had been diagnosed with either AD, MD, or both based on the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision. In addition, participants were screened for use of and dependency on other illegal substances. Each patient and control were initially assessed by an attending psychiatrist and then interviewed by a well-trained psychologist using the Chinese version of the Modified Schedule of Affective Disorder and Schizophrenia-Lifetime (SADS-L) to screen out other psychiatric conditions. The severity of depression was measured with the 17-item Hamilton Depression Rating Scale (HDRS); each patient with AD and comorbid MD (AD/MD) had an HDRS score ≥ 18, but patients with pure AD and controls scored < 10 on the HDRS on the day of the brain imaging study. Subjects were drug naive or had ceased psychotropic medication over 1 month prior to the study, but lorazepam (2–8 mg/d) was permitted in order to prevent alcohol withdrawal before the imaging study. Patients were also excluded if they had a comorbid Axis I or II mental disorder (except AD and MD), unstable medical conditions that could alter cerebral function including malignancy, cardiovascular disease, renal and hepatic diseases, head trauma with loss of consciousness, or any other neurological diseases.

The patient group consisted of 49 AD subjects recruited during intoxication or withdrawal who had consumed alcohol during the previous 72 h. With respect to the classifications of AD, our previous studies revealed that pure AD and AD/MD are discrete and genetically well-defined subgroups of AD. Therefore, subjects with AD were classified into 2 subgroups including pure AD, which was diagnosed in 28 individuals, and AD/MD, which was diagnosed in 21 individuals.

This study enrolled only male participants in order to avoid the potential confounding effects of sex on striatal DAT availability, because males present with more alcohol-associated problems than females. The control group consisted of 24 psychiatrically healthy male volunteers. Each subject was interviewed by a well-trained psychiatrist using SADS-L to exclude the possibility of major physical illness, psychiatric diseases, or substance abuse. None of the subjects was taking medications that could affect the central dopaminergic system during the study. The study was approved by the Institutional Review Board for the Protection of Human Subjects at the Tri-Service General Hospital (TSGH IRB No. 099-05-017), a medical teaching hospital belonging to the National Defense Medical Center in Taipei, Taiwan. Each participant provided written informed consent before the research was initiated. The procedures and raw data were monitored by the Intuitual Review Board at TSGH and National Research Program for Biopharmaceuticals. All raw data deposition in the laboratory of TSGH for the protection of human subjects, but these data permit study members to make data available under the procedures of TSGHIRB.

2.2. Imaging acquisition and data analysis

The SPECT procedure with 99mTc-TRODAT-1 for DAT imaging has been described elsewhere. TRODAT-1 kits were provided by the Institute of Nuclear Energy Research (Lungtan, Taiwan). All subjects consumed a low-protein diet for 24 h before the 99mTc-TRODAT-1 injection and SPECT measurement. The SPECT images were analyzed along the level of the callosum. The composite image from the 3 highest-activity basal ganglia slices from a given participant was co-registered with the corresponding computed tomography (CT) image to exclude possible brain lesions and to delineate standardized regions of interest (ROIs) for the caudate, putamen, and striatum. Magnetic resonance imaging was used to recheck the brain lesions if the CT scan produced inconclusive results. The defined ROIs were then manually applied to the other SPECT slices from the respective participant. The occipital cortices, which had low DAT concentrations, were also drawn in the same way and served as background areas. The uptakes of 99mTc-TRODAT-1 in various brain regions were measured 4 h after injection, and the specific
uptake ratio (SUR) of each region was calculated using the following equation: \( \text{ROI}_{\text{target}} = \text{ROI}_{\text{reference}} / \text{ROI}_{\text{reference}} \). The researcher drawing the ROIs on the images was blinded to the subject group.

2.3. Wisconsin Card Sorting Test

A computer-aided WCST was administered by an experienced psychologist on the same day as the SPECT scan. During the WCST, all participants were asked to match response cards with 4 key cards along 1 of 3 perceptual dimensions (color, form, or number). Verbal feedback (right or wrong) was given without revealing information about the dimensions. The test requires subjects to find the correct classification rule by trial and error. Once the subject chooses the correct rule, the subject must keep revealing information about the dimensions. The test requires flexibility in set-shifting. Spearman rho was carried out to examine the cross-sectional association between DAT availability and the WCST and HDRS parameters. Correlations between the SURs and other parameters (e.g., age, daily alcohol intake, and duration of AD) were also assessed with Pearson correlations.

3. RESULTS

3.1. Participants’ demographic characteristics and WCST parameters

Twenty-eight patients with pure AD (mean age 43.29 ± 10.32 years), 21 patients with AD/MD (mean age 38.57 ± 6.97 years), and 24 healthy controls (mean age 39.21 ± 8.87 years) were enrolled in this study. These subjects underwent SPECT scanning and completed the WCST and HDRS. Their demographic data are presented in Table 1. There were no significant differences in age among patients with pure AD, AD/MD, or healthy controls (P = 0.211). Notably, years of education and the numbers of cigarettes smoked per day were significantly different among the 3 groups (P < 0.001). The HDRS score was significantly higher in the AD/MD group than the pure AD group (P < 0.001) (Table 1).

Patients with AD were significantly impaired on several WCST measures, including total errors (P = 0.001 for pure AD, AD/MD, and total AD), nonperseverative errors (P = 0.003 for pure AD; P = 0.002 in both AD/MD and total AD), and categories completed (P = 0.001 for pure AD; P = 0.003 for total AD). These results were significant after Bonferroni correction for multiple comparisons.

Table 1

| Demographic characteristics and parameters of Wisconsin Card Sorting Test in people with pure AD, AD/MD, and healthy controls. | Pure AD (N = 28) | AD/MD (N = 21) | Healthy controls (N = 24) |
|---|---|---|---|
| **Age, y** | 43.29 ± 10.32 | 38.57 ± 6.97 | 39.21 ± 8.87 |
| **Education, y** | 13.00 ± 3.26 | 11.62 ± 2.36 | 16.50 ± 3.02 |
| **Smoker/nonsmoker** | 26.2 | 20.1 | 2.22 |
| **Duration of AD, y** | 22.79 ± 19.10 | 18.81 ± 13.78 | 0.83 ± 2.82 |
| **Age of alcohol dependence onset** | 12.43 ± 7.00 | 10.71 ± 6.77 | 0.663 |
| **Average daily alcohol intake, g** | 30.71 ± 9.78 | 27.86 ± 6.85 | 0.283 |
| **HDRS** | 166.07 ± 123.83 | 129.57 ± 52.01 | 0.454 |
| **Wisconsin Card Sorting Test** | 6.54 ± 3.42 | 19.38 ± 5.15 | <0.001 |
| **Total corrects** | 66.07 ± 17.71 | 70.29 ± 12.22 | 68.29 ± 8.55 |
| **Total errors** | 46.39 ± 27.59 | 42.81 ± 22.27 | 23.50 ± 18.28 |
| **Perseverative errors** | 23.43 ± 19.19 | 25.19 ± 23.57 | 12.13 ± 9.39 |
| **Nonperseverative errors** | 26.57 ± 21.86 | 22.71 ± 15.32 | 11.38 ± 9.85 |
| **Categories complete** | 3.36 ± 2.38 | 4.65 ± 2.83 | 5.38 ± 1.61 |
| **Failure to maintain set** | 1.11 ± 1.31 | 2.64 ± 6.80 | 0.79 ± 1.10 |

AD = alcohol dependence, AD/MD = alcohol dependence comorbid major depression, HDRS = 17-item Hamilton Depression Rating Scale, SD = standard deviations.

* Kruskal–Wallis test.
* Mann–Whitney U test.
* Pure AD vs healthy controls.
* AD/MD vs healthy controls.
* Pure AD vs AD/MD vs healthy controls.
Brain area Healthy controls (n = 24) Total AD (n = 49) P value AD/MD (n = 21) P value Pure AD (n = 28) P value

Caudate 2.87 ± 0.31 2.55 ± 0.43 0.001† 2.72 ± 0.34 0.085† 2.47 ± 0.46 <0.001†
Putamen 2.19 ± 0.25 1.86 ± 0.45 0.001† 2.05 ± 0.44 0.255† 1.71 ± 0.41 <0.001†
Striatum 2.52 ± 0.28 2.19 ± 0.39 <0.001† 2.37 ± 0.34 0.191† 2.06 ± 0.38 <0.001†

All entries for brain-specific uptake ratio in this table are presented as mean ± SD.

† Controls vs total AD.
AD/MD vs healthy controls.
Pure AD vs healthy controls.

(speciate P value would be 0.05/14 = 0.0036). In contrast, there were no significant differences in the WCST measures of total correct, perseverative errors, or failure to maintain set (Table 1).

3.2. DAT availability in healthy volunteers and patients with AD

In the healthy volunteers, the mean values of DAT availability in the striatum, putamen, and caudate were 2.52 ± 0.28, 2.19 ± 0.25, and 2.87 ± 0.31, respectively. Patients with total AD showed significantly lower DAT availability than healthy controls in the 3 brain regions (caudate, putamen, and striatum, P < 0.001, respectively; Table 2). The values of DAT availability in patients with AD were 2.19 ± 0.39 for striatum, 1.86 ± 0.45 for putamen, and 2.55 ± 0.43 for caudate, respectively. Moreover, this effect was more pronounced in the pure AD group compared with the control group (caudate, putamen, and striatum, P < 0.001) (Fig. 1, Table 2).

The GEE analysis was used to explore the effects on the SURs of variables such as age, education, smoking status, number of cigarettes smoked per day, and group. The caudate and putamen SURs differed significantly from those of the total striatum (P < 0.001). When analyzing the correlation between age and SUR, a significant effect was found (P < 0.001). Number of cigarettes smoked per day did not have any significant association with SUR (Table 3).

3.3. Relationship between WCST parameters and DAT availability

When analyzing the relationship between striatal SUR, years of AD, and amount of daily alcohol intake, we found a significant association between striatal SUR and years of AD (rho = −0.455, P < 0.001) (Fig. 2, Table 3).
The relationship between WCST tests and striatal DAT availability in patients with pure AD by Spearman correlation revealed that a marginal association was observed for total errors ($\rho = -0.407, P = 0.032$), perseverative errors ($\rho = -0.385, P = 0.043$), and categories completed ($\rho = -0.379, P = 0.047$) (Table 4). Nevertheless, these marginal results were insignificant after Bonferroni correction (conservative $P$ value would be 0.05/24 = 0.0021). In addition, there is no association between DAT availability and the WCST parameters in both total AD and AD/MD groups. The healthy subjects reached statistical significance between striatal DAT availability and total errors ($\rho = -0.702, P = 0.001$) (Fig. 3), perseverative errors ($\rho = -0.688, P < 0.001$), failure to maintain set ($\rho = -0.408, P < 0.001$), and nonperseverative errors ($\rho = -0.578, P = 0.003$) (Table 4).

A significant negative correlation between the HDRS scores and DAT availability was found in the AD/MD group ($\rho = -0.539, P = 0.012$ for the striatum; $\rho = -0.435, P = 0.048$ for the putamen; and $\rho = -0.558, P = 0.009$ for the caudate), but not in the pure AD and healthy control groups ($P > 0.05$) (Fig. 4).

### 4. Discussion

#### 4.1. Brain DAT availability in patients with AD

DAT dysfunction is an important factor in the pathogenesis of both AD and MD; however, previous studies have not examined DAT availability in patients within different subgroups of AD. This study showed significantly lower DAT availability in the brains of male patients with AD compared with those of healthy controls. Of the different subgroups we examined, this study found that the pure AD group exhibited the lowest DAT availability compared to that in the AD/MD and control groups. Our results are similar to prior neuroimaging studies in patients with AD,[8,10,11] but differ from those of others.[26,27]

These conflicting results may be attributed to several factors. First, the timing of performing brain imaging during different periods may influence the results of DAT availability in patients with AD. A human study using [123I]-β-CIT SPECT on patients with AD found a decrease in DAT availability during the withdrawal period followed by a significant increase after a period of abstinence.[9] The results of that study indicated that DAT availability might be transiently reduced in the alcohol withdrawal state and gradually increased after a period of abstinence. In order to exclude the time-effect on brain DAT availability, our patients were enrolled during continued drinking status and the brain imaging was performed within the early withdrawal state (within 72 hours of the last drink). Thus, the time factor is unlikely to have interfered with our results. Second, the selection of the radioligand may influence the analysis of data. For example, [123I]-β-CIT is not a specific radioligand for DAT because it also has affinity for serotonin[28] and norepinephrine.[19] The specificity of the radioligands and semiquantitative techniques will provide more objective information and diagnostic accuracy on DAT availability.[10] Therefore, it is important to choose highly specific tracers in the investigation of DAT availability. At present, $[^{99m}Tc]$TRODAT-1 is the most specific radioligand for DAT,[31] and it seems to be a suitable radiotracer for further imaging studies of DAT availability in AD and MD. Third, patients with AD are usually comorbid with depressive disorder,[20] and previous

---

**Table 4**

| WCST parameter | Striatum | Pure AD (n = 28) $\rho$ coefficient $^*$ ($P$ value) | AD/MD (n = 21) $\rho$ coefficient $^*$ ($P$ value) | Total AD (n = 49) $\rho$ coefficient $^*$ ($P$ value) | Healthy controls (n = 24) $\rho$ coefficient $^*$ ($P$ value) |
|---------------|---------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| TC            | 0.030 (0.877) | $-0.132$ (0.568) | $-0.002$ (0.992) | $-0.237$ (0.265) |
| TE            | $-0.407$ (0.032) | 0.159 (0.490) | $-0.154$ (0.292) | $-0.702$ (<0.001) |
| PE            | $-0.385$ (0.043) | $-0.148$ (0.521) | $-0.256$ (0.076) | $-0.688$ (<0.001) |
| NPE           | $-0.285$ (0.142) | 0.470 (0.032) | 0.058 (0.690) | $-0.578$ (0.003) |
| CC            | 0.379 (0.047) | $-0.111$ (0.640) | 0.225 (0.124) | 0.319 (0.129) |
| FMS           | $-0.016$ (0.934) | $-0.298$ (0.301) | $-0.067$ (0.679) | $-0.408$ (<0.001) |

$AD = $ alcohol dependence, $AD/MD = $ alcohol dependence comorbid major depression, $CC = $ categories completed, $DAT = $ dopamine transporter, $FMS = $ failure to maintain set, $NPE = $ nonperseverative errors, $PE = $ perseverative errors, $TC = $ total corrects, $TE = $ total errors, $WCST = $ Wisconsin Card Sorting Test.

$^*$ Spearman rank correlation.

---

Figure 3. Graph showing correlation of striatal-specific uptake ratio of $[^{99m}Tc]$TRODAT-1 with total errors. Significant correlation between these parameters existed in healthy controls, but not in AD group. AD = alcohol dependence.
be investigated further.

smoking on DAT availability remains controversial and needs to be further investigated.

studies have reported higher DAT availability in female.[21,35] Hence, major depression (MD) is one of the confounding factors in the investigation of DAT availability in patients with AD, but previous brain DAT imaging studies could not exclude these confounding factors.[10,11] In order to evaluate the influence of depressive effects on brain DAT activity, the present study recruited patients with AD/MD and pure AD. Thus, the results of incongruent reduction of DAT availability in different subgroups of AD (positive results in pure AD, and negative results in AD/MD, Table 2) may explain previous controversial results. Although this is the first study to examine brain DAT availability of patients with AD in different subgroups, the confounding factors of different personality and MD in patients with AD should be further investigated.

4.2. Age, sex, and smoking status on DAT availability

Age, sex, and smoking behavior may have confounding effects on DAT availability. Our results found a significant negative correlation between brain DAT availability and age in healthy controls (rho = −0.485, P = 0.016), which is similar with the findings of other reports.[21,34] However, we did not find a strong relationship between striatal DAT availability and age in patients with AD/MD (rho = −0.325, P = 0.150). These data indicate that alcohol and depression may play a more significant role than age in influencing DAT availability. With respect to sex effects, prior studies have reported higher DAT availability in female.[21,35] This study showed no age difference between patients with AD and healthy controls and only enrolled male subjects, thus abolishing age and sex as confounding factors in this study.

Cigarette smoking may have indirect effects on the mesolimbic dopaminergic system.[36] Yang et al.[37] and Newberg et al.[38] reported a decrease in striatal DAT availability in smokers compared with nonsmokers; however, this association was not found in another study.[39] The present study found no correlation between the number of cigarettes smoked per day and striatal DAT availability (rho = −0.269, P = 0.062, data not shown) in the total patients with AD. However, the effect of smoking on DAT availability remains controversial and needs to be investigated further.

4.3. Cognitive function and striatal dopamine dysfunction in patients with AD

The WCST is a neuropsychological assessment tool widely used to assess frontal lobe activity and corticostratal pathway function.[40] The DAT has been reported to be associated with cognitive functions in previous studies.[41,42] Spatial working memory is impaired in DAT knockout mice.[43] Selective damage of the dopaminergic neurons in rats can lead to cognitive deficits, particularly when the mesocorticolimbic pathway of the dopaminergic system is involved.[44] This study found a negative correlation between brain DAT availability and the performance of WCST tasks in the control group (Fig. 3, Table 4). These results are consistent with our previous study[10] and other studies in human,[45,46] which suggest that striatal dopaminergic function may play an important role in performance on cognitive tests.

Low DAT availability and cognitive dysfunction were found among different AD subgroups, but we showed no relationship between brain DAT availability and performance on the WCST in patients with total AD and AD/MD. Although the early withdrawal symptoms may 1 possibility to influence the performance on WCST tasks among patients with AD, other possibilities such as inflammatory factors and genetic heterogeneity need to further investigated in the future.

4.4. Association between the HDRS scores and DAT availability in patients with AD

This study found that the HDRS scores are negatively correlated with DAT availability in patients with AD/MD over the caudate, the putamen, and the striatum. These results fit the “low dopamine hypothesis” for explaining depressive symptoms and we suggest that the dopamine-depletion-induced down-regulation of the DAT occurs during depressive episodes in patients with AD/MD. The negative correlation is consistent with previous studies of depressive symptoms in Parkinson disease[47,48]; however, the relationship could not be found in patients with MD only[49,50] or patients with AD only.[51] Although prior studies analyzed the relationship between depressive symptoms and DAT availability in the brain, these studies used different patient groups, which might have affected the measures of dopamine availability in the brains of patients with depression. MD is a common comorbidity in patients with AD, but there are no studies on the relationship between depressive severity and DAT availability in patients with AD/MD comorbid with a current major depressive episode. Our results suggest that decreased DAT availability (density) in the striatum may play an important and necessary role in the development of depressive symptoms in patients with AD/MD. Therefore, dopaminergic-related antidepressants may be beneficial in the treatment of depressive alcoholism.

5. Limitations

Result of the present study should be interpreted with caution because of the following limitations. First, the small sample size of this study reduced statistical power. In order to prevent possible type I errors, we recruited only male patients within 2 subgroups of AD from a Han Chinese population, thus limiting the effects of ethnicity and multifactorial diversity. Second, the study design used a cross-sectional method. Some of the patients initially diagnosed with MD might be more accurately diagnosed with bipolar disorder after a subsequent manic or hypomanic episode.
Third, our subjects with AD had taken lorazepam to prevent withdrawal syndromes before SPECT imaging, and there is evidence to suggest that benzodiazepine may interfere with levels of extracellular dopamine. Fourth, patients with AD/MD may have differences in length of illness, duration of episode, quality of sleep, and severity of symptoms, which may have influenced SUR values.

6. Conclusions

The present findings suggest that the incongruent reduction of DAT availability in different subgroups of AD may play a pathophysiological role in the development of AD, and different drinking behaviors may influence the stabilization of brain dopamine levels. We found that decreased DAT availability may be associated with neurocognitive deficits, and that DAT availability may play an important role in normal neurocognitive function. Moreover, the availability of brain striatal dopamine may influence the severity of depressive symptoms in patients with AD/MD. To confirm this, further studies are required to establish consistency of the incongruent reduction of DAT availability in different clinical subgroups.

Acknowledgment

We would like to thank Miss Yun-Hsin Lin for her assistance in the preparing this manuscript.

References

[1] Ma H, Zhu G. The dopamine system and alcohol dependence. Shanghai Arch Psychiatry 2014;26:6-11.
[2] Adermark L, Clarke RB, Olsson T, et al. Implications for glycine receptors and astrocytes in ethanol-induced elevation of dopamine levels in the nucleus accumbens. Addict Biol 2011;16:43-54.
[3] Tye KM, Mirzabekov JJ, Warden MR, et al. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature 2013;493:337-41.
[4] Hibbeler JR, Linola M, Umbau JC, et al. Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. Biol Psychiatry 1998;44:235-42.
[5] Willner P. Dopamine and depression: a review of recent evidence. II. Theoretical approaches. Brain Res 1983;287:225-36.
[6] Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 2003;4:13-25.
[7] Gainetdinov RR. Dopamine transporter mutant mice in experimental neuropharmacology. Naunyn Schmiedebergs Arch Pharmacol 2008;377:101-13.
[8] Repo E, Kuukka JT, Bergstrom KA, et al. Dopamine transporter and D2-receptor density in late-onset alcoholism. Psychopharmacology 1999;149:314-8.
[9] Laine TP, Ahonen A, Torniainen P, et al. Dopamine transporters increase in patients with alcohol dependence. Mol Psychiatry 1999;4:189-91, 04-5.
[10] Yen CH, Yeh YW, Liang CS, et al. Reduced dopamine transporter availability and neurocognitive deficits in male patients with alcohol dependence. PLoS ONE 2015;10:e0151017.
[11] Tupala E, Hall H, Manteer T, et al. Dopamine receptors and transporters in the brain reward circuits of type 1 and 2 alcoholics measured with human whole hemisphere autoradiography. Neuroimage 2003;19:145-55.
[12] Grant BF, Strain FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004;61:807-16.
[13] Kram ML, Kramer GL, Ronan PJ, et al. Dopamine receptors and learned helplessness in the rat: an autoradiographic study. Prog Neuro-psychopharmacol Biol Psychiatry 2002;26:619-45.
[14] Zangen A, Nakash R, Overstreet DH, et al. Association between degree of behavior and absence of serotonin-dopamine interaction in the nucleus accumbens. Psychopharmacology (Berl) 2001;155:434-9.
[15] D’Aquila PS, Collu M, Gessa GL, et al. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000;405:565-73.
[16] Nowakowska K, Jablowska K, Borkowska A. Cognitive dysfunctions in patients with alcohol dependence. Psychiatr Pol 2007;41:693-702.
[17] Nyhus E, Barcelo F. The Wisconsin Card Sorting Test and the cognitive assessment of prefrontal executive functions: a critical update. Brain Cogn 2009;71:437-51.
[18] Schulte MT, Ramo D, Brown SA. Gender differences in factors influencing alcohol use and drinking trajectory among adolescents. Clin Psychol Rev 2009;29:535-47.
[19] Huang S-Y, Lin WW, Wan FJ, et al. Monoamine oxidase-A polymorphisms might modify the association between the dopamine D2 receptor gene and alcohol dependence. J Psychiatry Neurosci 2007;32:185-92.
[20] Huang S-Y, Lin WW, Ko HC, et al. Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin Exp Res 2004;28:374-8.
[21] Koch W, Pogarell O, Popperl G, et al. Extended studies of the striatal uptake of [99mTc]-NC00697 in healthy volunteers. J Nucl Med 2007;48:27-34.
[22] Mozley PD, Acton PD, Barraclough ED, et al. Effects of age on dopamine transporters in healthy humans. J Nucl Med 1999;40:1812-7.
[23] Nolen-Hoeksema S. Gender differences in risk factors and consequences for alcohol use and problems. Clin Psychol Rev 2004;24:981-1010.
[24] Huang WJ, Yao WJ, Wei SP, et al. Reproducibility of [99Tc]-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson’s disease. J Nucl Med 2004;45:207-13.
[25] Heaton RC, Talley JL, Kay G, et al. Wisconsin Card Sorting Test Manual: Revised and Expanded. Odessa:Psychological Assessment Resources, Inc; 1993.
[26] Volkow ND, Wang GJ, Fowler JS, et al. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res 1996;20:1594-8.
[27] Cosgrove KP, Krantzler E, Frohlich EB, et al. Dopamine and serotonin transporter availability during acute alcohol withdrawal: effects of comorbid tobacco smoking. Neuropsychopharmacology 2009;34:2218-26.
[28] Laruelle M, Baldwin RM, Malison RT, et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309.
[29] Farde L, Hallidin C, Muller L, et al. PET study of [11C]beta-CIT binding to monoamine transporters in the monkey and human brain. Synapse 1994;16:93-103.
[30] Djang DS, Janssen MJ, Bohnen N, et al. SNM practice guideline for dopamine transporter imaging with 123I-labeled TRODAT-1. J Nucl Med 2012;53:154-63.
[31] Dresel SH, Kung MP, Ploss K, et al. Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc]TRODAT-1 to the central dopamine transporters in rats. Eur J Nucl Med 1998;25:31-9.
[32] Brunswick DJ, Amsterdam JD, Mozley PD, et al. Greater availability of brain dopamine transporters in major depression shown by [99mTc]TRODAT-1 SPECT imaging. Am J Psychiatry 2003;160:1836-41.
[33] Amsterdam JD, Newberg AB, Soeller I, et al. Greater striatal dopamine transporter density may be associated with major depressive episode. J Affect Disord 2012;141:425-31.
[34] Lavallée J, Boori J, Reneman L, et al. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 2000;27:867-9.
[35] Varrone A, Dickson JC, Tossici-Bolt L, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging 2013;40:213-27.
[36] Miller LR, Mukherjee S, Ansah TA, et al. Cigarette smoke and dopaminergic system. J Biochem Mol Toxicol 2007;21:325-35.
[37] Yang YK, Yao WJ, Yeh TL, et al. Decreased dopamine transporter availability in male smokers—a dual isotope SPECT study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:274-9.
[38] Newberg A, Lerman C, Wintering N, et al. Dopamine transporter binding in smokers and nonsmokers, Clin Nucl Med 2007;32:452-5.
[39] Thomsen GK, Knudsen GM, Jensen PS, et al. No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT. EJNMMI Res 2013;3:39.
[40] Gonzalez-Hernandez JA, Pita-Alcorta C, Cedeno I, et al. Wisconsin Card Sorting Test synchronizes the prefrontal, temporal and posterior association cortex in different frequency ranges and extensions. Hum Brain Mapp 2002;17:37–47.
[41] Hsieh PC, Yeh TL, Lee IH, et al. Correlation between errors on the Wisconsin Card Sorting Test and the availability of striatal dopamine transporters in healthy volunteers. J Psychiatry Neurosci 2010;35:90–4.
[42] Cropley VL, Fujiya M, Innis RB, et al. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry 2006;59:898–907.
[43] Li B, Arine Y, Hall FS, et al. Impaired spatial working memory and decreased frontal cortex BDNF protein level in dopamine transporter knockout mice. Eur J Pharmacol 2010;628:104–7.
[44] Nicoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;67:53–83.
[45] Tihonen J, Vilkman H, Rasanne P, et al. Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography. Mol Psychiatry 1998;3:156–61.
[46] Landau SM, Lal R, O’Neil JP, et al. Striatal dopamine and working memory. Cereb Cortex 2009;19:445–54.
[47] Weintraub D, Newberg AB, Cary MS, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med 2003;46:227–32.
[48] Rektorova I, Srovnalova H, Kubikova R, et al. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson’s disease. Mov Disord 2008; 23:1580–7.
[49] Lasenon-Balk T, Kukka J, Vinamaki H, et al. Striatal dopamine transporter density in major depression. Psychopharmacology (Berl) 1999;144:282–5.
[50] Argylan M, Szabo Z, Kanyo B, et al. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord 2005;89:115–23.
[51] Laine TP, Ahonen A, Rasanne P, et al. Dopamine transporter availability and depressive symptoms during alcohol withdrawal. Psychiatry Res 1999;90:153–7.
[52] Bentue-Ferrer D, Reymann JM, Tribut O, et al. Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam. Eur Neuropsychopharmacol 2001;11:41–50.